Somatic Cancer
Seraseq® cfRNA Fusion Mix
Details
Specifications
As diagnostic testing for chromosomal translocations and other complex structural variants continues to shift from single-site methods such as Fluorescent In Situ Hybridization (FISH) and targeted reverse transcription PCR (RT-PCR) to highly multiplexed next-generation sequencing (NGS) assays, there is an increasing need for highly multiplexed reference materials covering such alterations which may be rare or difficult to obtain from patient samples. SeraCare continues to innovate to address this critical market need with an expanded reference material designed for use with NGS assays that detect gene fusions via sequencing of RNA transcripts. With the continued utility of liquid biopsy improving cancer management, we are introducing a purpose-built reference material to support cell-free RNA (cfRNA) assays.
SeraCare has long supported RNA fusion studies with many novel RNA fusion reference material offerings. Seraseq cfRNA Fusion Mix is a new product which is complementary to existing RNA fusion product offerings.
Seraseq cfRNA Fusion Mix is a highly multiplexed pan-cancer RNA reference material containing 19 RNA fusion transcripts in a single sample. This will allow for more rapid validation of assays using fewer samples and more comprehensive performance monitoring of routine NGS runs.
Product Specifications - Sarcoma Plus RNA Fusion Mix |
|
# of Variants |
30 |
# of vials/kit |
1 |
Fill Volume |
20 µl |
Concentration |
25 ng/µl |
Total Mass |
500 ng |
Format |
Purified DNA in buffer (Tris/EDTA) |